New HIV vaccine strategy aims to prime and boost immune defenses

NCT ID NCT07675629

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Worcester HIV Vaccine Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a two-part HIV vaccine in healthy adults who do not have HIV. The vaccine uses a DNA 'prime' followed by a protein 'boost' to train the immune system against multiple HIV strains. Researchers are checking if the vaccine is safe and whether it triggers a strong immune response. The trial includes 126 volunteers and compares two different adjuvants (substances that boost the immune reaction).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PDPHV HIV-1 vaccine (DNA prime and gp120 protein boost with adjuvant)
What this could lead to: If successful, this could pave the way for an effective HIV vaccine, potentially preventing infection.
What could go wrong: This is an early-phase trial focused on safety and immune response, not prevention. The vaccine may not produce strong enough immunity to protect against HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Emavundleni Clinical Research Site, Desmond Tutu Health Foundation

Cape Town, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.